The global tissue diagnostics market size was estimated to be US$ 4.9 billion in 2021 and is expected grow at a CAGR of 6% between 2023 to 2032.
A crucial tool in detecting, monitoring, and treating various cancer situations is tissue diagnostics. Through biopsy—a procedure in which a sample is taken from the area of interest, such as skin, tissue, or a tumour, for further diagnosis—disease signs and symptoms are identified. The primary purposes of biopsies are cancer screening and transplant organ rejection detection.
A biopsy is performed to determine the most likely source of malignant and non-cancerous tissue that a CT scan or X-ray cannot detect. Numerous biopsy techniques, including endoscopic biopsy, bone marrow biopsy, skin biopsy, kidney biopsy, liver biopsy, and prostate biopsy, are used depending on the region of the sample collection.
Tissue diagnostics equipment and technique advancements allow quick and accurate diagnosis and evaluation of diseases affecting the tissues. The global tissue diagnostics market is driven by increased cancer incidences, a rapidly aging population, and healthcare spending. However, budget restrictions and a high level of consolidation limit market expansion. Additionally, the substantial potential for market expansion is provided by emerging markets and the growing usage of personalized medicine.
A slight expansion in the global market accompanied the COVID-19 pandemic in 2020. The impact of the spread of the coronavirus infection was being studied, and possible drugs and therapies were being developed by research facilities worldwide. However, research into cancer treatment methods and instruments was also ongoing during the epidemic, providing promising growth potential.
Market Growth Drivers
The global increase in cancer rates is propelling the market's expansion.
The World Health Organization (WHO) estimates that cancer will cause 10 million deaths worldwide. Cancer deaths in low- and middle-income nations account for over 70% of fatalities. Early detection is crucial for lowering mortality, increasing survival rates, and saving money on treatment. Globally, cancer costs are rising, placing great economic hardship on the nations.
The market is now characterized by the introduction of digital pathology and automation in tissue diagnostics.
Automated tissue diagnostics are becoming more popular due to the assays' enhanced technical performance, which lowers reagent costs and assay time. The demand for automation in tissue diagnostics systems is also influenced by the management of massive amounts of data and the scarcity of qualified pathologists. One of the advancements in tissue diagnostics is the automation of staining equipment and new platforms like digital immunohistochemistry (IHC).
Consumables used in diagnosis are limitedly used materials. The substantial market shareholding of the following sector is related to developing novel indicators, other comestibles, and the ongoing need for consumables. Consider the U.S. The National Cancer Institute's (NCI) Early Detection Research Network (EDRN), a cooperative group of researchers from the academic and industrial sectors, is dedicated to the systematic discovery, imaging techniques, and validation of biomarkers to identify cancers in their earliest stages and to determine the risk of increasing cancer decease. These report projects drive the need for tissue diagnostics consumables.
In contrast to traditional enzyme staining methods, immunohistochemistry can distinguish between various kinds of cancers, due to which it is chosen for cancer diagnosis. Due to the widespread use of cancer screening, advances in immunohistochemistry technology, and the accessibility of remuneration policies for IHC-based tests, this market category holds a sizable market share.
Breast cancer is highly prevalent and steadily increasing worldwide. WHO has estimated that millions of women will receive a breast cancer diagnosis worldwide. Because of the high incidence of breast cancer and the existence of financing initiatives to assist research and initial detection of breast cancer, this category holds a sizable market share.
Due to the rising incidence of cancer worldwide, the high patient flow to hospitals and diagnostic labs, and increased funding for the adoption of cutting-edge technology, this market segment holds a sizable market share.
North America is anticipated to dominate the tissue diagnostics market during the projected period, followed by Europe and the Asia-Pacific region. Furthermore, the North American area is credited with accelerating market expansion in the upcoming years due to substantial spending on research & development activities in the biotechnology and medical equipment organizations and the extensive adoption of novel technologies.
On the other hand, Asia Pacific will likely experience substantial expansion during the projected period. The need for diagnosis and treatment in this region is anticipated to rise due to the development of the medical tourism industry in countries like China and India. The market for tissue diagnostics will also develop due to the rise in cancer incidence and other illnesses.
However, a lack of knowledge regarding tissue diagnostics in several developing economies may impede the market's growth trajectory throughout the projection period.
Abbott Laboratories, Agilent Technologies, BIOMÉRIEUX, BioGenex, Cell Signalling Technology, Danaher Corporation, F. Hoffmann-La Roche Ltd, General Electric Company (GE Healthcare), Inc., Merck KGaA, and Koninklijke Philips N.V.
By End User:
The fastest CAGR is being experienced in Asia Pacific.
The rising cancer cases and technological advancements drive the tissue diagnostics market.
Lack of knowledge and awareness is restraining the tissue diagnostics market.
The tissue diagnostics market size was estimated to be US$ 4.9 billion in 2021.
The tissue diagnostics market is expected to grow at a compound annual growth rate of 6% from 2023 to 2032.
Copyright © 2023 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved